Metipranolol

Metipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Brands
Adult Dose
Dose: 1 drop
Single Dose: 1 (1)
Frequency: 12 hourly
Route: Opthalmic
Instructions:
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Metipranolol is 309.40.
Contraindications
Metipranolol is contraindicated in conditions like Cardiogenic shock,Cardiac failure,Bradycardia,Obstructive pulmonary disease,Bronchial asthma,Hypersensitivity to any component of product.
Effects
The severe or irreversible adverse effects of Metipranolol, which give rise to further complications include Conjunctivitis, Conjunctival Leucoplakia.The signs and symptoms that are produced after the acute overdosage of Metipranolol include Bradycardia, Uveitis, Hypertension, Cardiac failure, Atrial fibrillation, Myocardial infarction.The symptomatic adverse reactions produced by Metipranolol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Dyspnea, Blurred vision, Rashes, Allergic reactions, Depression, Edema, Rhinitis, Bronchitis, Photophobia, Abnormal vision, Arthiritis.
Indications
Metipranolol is primarily indicated in conditions like Ocular hypertension, Open-angle glaucoma.
Interactions
No data regarding the interactions of Metipranolol was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tablets Store at room temperature, . Protect from Heat.
Warnings
Metipranolol, or other beta-blockers, should not, in general, be administered to patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity. Because of potential effects of beta-adrenergic receptor blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with metipranolol, alternative therapy should be considered. Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Patients should be advised that Metipranolol contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following OptiPranolol administration.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.